{
    "clinical_study": {
        "@rank": "126002", 
        "arm_group": {
            "arm_group_label": "olaparib tablet monotherapy", 
            "arm_group_type": "Experimental", 
            "description": "olaparib tablet"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study will be to investigate the safety and tolerability of olaparib\n      tablet when given orally to Japanese patients with advanced solid malignancies.  In\n      addition, the pharmacokinetic profile, MTD (if possible) and efficacy of olaparib will be\n      investigated."
        }, 
        "brief_title": "Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Advanced Solid Malignancies"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "MTD - maximum tolerated dose"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects diagnosed with advanced solid malignancies who are refractory to standard\n             therapies or for which no standard therapy exists.\n\n          -  Subjects who have overall good overall general condition.\n\n          -  Subjects who agree to hospitalisation from starting olaparib to multiple dose period\n             at day 15.\n\n          -  Evidence of non-childbearing status for women of childbearing potential, or\n             postmenopausal status.\n\n          -  Subjects who have at least one lesion (measurable and/or non-measurable) that can be\n             accurately assessed by CT/MRI at baseline and follow up visits\n\n        Exclusion Criteria:\n\n          -  Subjects who received any previous treatment with a PARP (poly adenosine\n             diphosphate-ribose polymerase) inhibitor, including olaparib.\n\n          -  Subjects receiving inhibitors of CYP3A4 (cytochrome P450 3A4).\n\n          -  Subjects with symptomatic uncontrolled brain metastases.\n\n          -  Subjects with myelodysplastic syndrome/acute myeloid leukaemia.\n\n          -  Subjects with a known hypersensitivity to olaparib or any of the excipients of the\n             product."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813474", 
            "org_study_id": "D081BC00001"
        }, 
        "intervention": {
            "arm_group_label": "olaparib tablet monotherapy", 
            "description": "tablet oral", 
            "intervention_name": "olaparib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cancer", 
            "Tumour", 
            "Solid Malignancies"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies", 
        "overall_official": {
            "affiliation": "Global Medicines Development", 
            "last_name": "Thomas Morris, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Investigation of the safety and tolerability of olaparib tablet by assessing of CTCAE (Common Terminology Criteria Adverse Events) grade in Japanese patients with advanced solid malignancies.", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 months."
            }, 
            {
                "measure": "Investigation of the safety and tolerability of olaparib tablet by assessing of frequency of adverse events in Japanese patients with advanced solid malignancies.", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 months."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813474"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Day 1 and 2 single dose period. Day 1 and 15 multiple dose period day. Pre dose of single dose period day 1 at: 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12h,day 2 at 24h and day 3 at 48h (same day as multiple dose period day 1). Pre dose of multiple dose period day 15 at: 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8h and 12h", 
            "measure": "Evaluation of pharmacokinetics of olaparib (Cmax, Tmax, AUC - area under curve).", 
            "safety_issue": "No", 
            "time_frame": "At day 1 and 2 single dose period, day 1 and 15 multiple dose period day."
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}